Amantadine in the treatment of Parkinson's disease and other movement disorders
The efficacy of amantadine in the symptomatic treatment of patients with Parkinson's
disease, discovered serendipitously more than 50 years ago, has stood the test of time and …
disease, discovered serendipitously more than 50 years ago, has stood the test of time and …
Levodopa-induced dyskinesia in Parkinson's disease: pathogenesis and emerging treatment strategies
The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …
[HTML][HTML] Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis
G DeMaagd, A Philip - Pharmacy and therapeutics, 2015 - ncbi.nlm.nih.gov
Parkinson’s Disease and Its Management - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search …
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search …
Direct and indirect pathways of basal ganglia: a critical reappraisal
The basal ganglia are subcortical nuclei controlling voluntary actions and have been
implicated in Parkinson's disease (PD). The prevailing model of basal ganglia function …
implicated in Parkinson's disease (PD). The prevailing model of basal ganglia function …
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
In silico molecular docking analysis of karanjin against alzheimer's and parkinson's diseases as a potential natural lead molecule for new drug design, development …
Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders
that have emerged as among the serious health problems of the 21st century. The …
that have emerged as among the serious health problems of the 21st century. The …
Levodopa in Parkinson's disease: current status and future developments
N Tambasco, M Romoli… - Current …, 2018 - ingentaconnect.com
Background: Ever since the pioneering reports in the 60s, L-3, 4-Dioxyphenylalanine
(levodopa) has represented the gold standard for the treatment of Parkinson's Disease (PD) …
(levodopa) has represented the gold standard for the treatment of Parkinson's Disease (PD) …
Clinical spectrum of levodopa‐induced complications
CC Aquino, SH Fox - Movement Disorders, 2015 - Wiley Online Library
The first years of Parkinson disease (PD) treatment are marked by good and sustained
responses to dopaminergic therapy. With disease progression and longer exposure to …
responses to dopaminergic therapy. With disease progression and longer exposure to …
Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts
KA Jellinger - Movement disorders, 2012 - Wiley Online Library
Abstract Parkinson's disease (PD), one of the most frequent neurodegenerative disorders, is
no longer considered a complex motor disorder characterized by extrapyramidal symptoms …
no longer considered a complex motor disorder characterized by extrapyramidal symptoms …
The dopaminergic system promotes neprilysin-mediated degradation of amyloid-β in the brain
N Watamura, N Kakiya, R Fujioka, N Kamano… - Science …, 2024 - science.org
Deposition of amyloid-β (Aβ) in the brain can impair neuronal function and contribute to
cognitive decline in Alzheimer's disease (AD). Here, we found that dopamine and the …
cognitive decline in Alzheimer's disease (AD). Here, we found that dopamine and the …